$NGEN News

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028

NervGen Pharma: The Upside Is Large, But Phase 3 Decides Everything

NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript

NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026

NervGen to Host Inaugural R&D Day on September 30, 2026

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15

Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Pharma Increases Mixed Shelf Offering From $150M To $250M

Why Is NervGen Pharma Stock Gaining Tuesday?

NervGen Pharma Announces Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery With NVG-291 In The Phase 1B/2a CONNECT SCI Study; Notes 100% Of Subjects Were Classified As Responders Against 10% For Placebo

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Proposed Public Offering of Securities

NervGen Pharma Announces Commencement Of Public Offering Of Common Shares

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

HC Wainwright & Co. Initiates Coverage On NervGen Pharma with Buy Rating, Announces Price Target of $18